Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

JNJ 100.21 +0.37 (0.37%)
price chart
Johnson & Johnson to phase out potentially harmful chemicals by 2015
(CBS/AP) Johnson & Johnson says it will remove carcinogenic chemicals and other potentially harmful substances from nearly all its adult toiletries and cosmetic products worldwide within 3.5 years.
Johnson & Johnson to Remove Formaldehyde From Products  New York Times
Johnson & Johnson Removing 'Chemicals Of Concern" From Adult ...  Huffington Post
Johnson & Johnson Announces a Ban on Harmful Chemicals in Products
Johnson & Johnson made the landmark announcement this week that it would ban harmful chemicals from their products. The company has already made the pledge to remove toxic chemicals from its baby products by 2013.
The Real Lesson of Formaldehyde In Baby Shampoo  TIME
Globe trotter: Johnson & Johnson comes clean  Economic Times
Berkshire Cuts Johnson & Johnson Stake
Jennifer Chelune, a spokeswoman for the Cincinnati-based company, declined to comment. Berkshire pared its holdings of Johnson & Johnson by about two-thirds to 10.3 million shares. The world's biggest health-products maker was ordered in April to pay ...
Buffett's Berkshire cuts stakes in J&J, Kraft, P&G  MarketWatch
Buffett's Berkshire Slashes Consumer Stock Holdings  CNBC.com
Johnson & Johnson Eyes China's Baby Market
Johnson & Johnson is rumored to be considering the acquisition of a local baby-care product vendor Shanghai Elsker in China, a move that could strengthen its foothold in the rapidly-growing Chinese baby-care market.
Johnson & Johnson unit recalls bone putty
The health regulator said certain lots of bone putty made by Johnson & Johnson unit Synthes were recalled as there was potential for the putty to catch fire if it came in contact with electrosurgical cautery systems during surgery.
Trials for Alzheimer's Drug Halted After Poor Results
Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer's drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease.
Alzheimer's drug trials ended by Pfizer and Johnson & Johnson; Elan ...  FinFacts Ireland
Pfizer, J&J scrap Alzheimer's studies as drug fails  Reuters
Genmab, Johnson & Johnson agree $1.1 billion cancer deal
Janssen Biotech will make an upfront payment of $55 million for the license and Johnson & Johnson Development Corp would invest 475 million Danish crowns ($80 million) in new Genmab shares, the company said.
Genmab Surges on Johnson & Johnson Cancer Pact: Copenhagen Mover  Bloomberg
J&J grabs Genmab's promising leukemia antibody in $1.1B deal  FierceBiotech
Johnson & Johnson Still Hates Women With Heavier Than Normal Periods
Last year the internet was in an uproar because Johnson & Johnson discontinued OB Ultra Absorbency tampons. By internet, I mean women's sites, of course.
No More Tears: Johnson & Johnson Cleans Up Its Act and Removes Carcinogens
Prompted by growing concerns raised by the Campaign for Safe Cosmetics, Johnson & Johnson makers of Aveeno, Neutrogena, and Johnson's Baby Shampoo, announced today that it will be removing carcinogens and other toxic chemicals from its baby ...
Related articles »  
Johnson & Johnson Unit Settles State Cases Over Risperdal
Johnson & Johnson announced Thursday that its pharmaceutical unit had reached a $181 million consumer fraud settlement with 36 states and the District of Columbia over its marketing of Risperdal, an antipsychotic drug.
Johnson Johnson subsidiary to pay record amount to settle off-label ...  Seattle Post Intelligencer (blog)
Here Are The Allegations That Spurred J&J To Pay A $181 Million ...  Business Insider